Quick Answer
ENDONOVO THERAPEUTICS, INC. reported Total Revenue of $135.4 thousand for fiscal year 2022.
ENDONOVO THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Total Revenue | $135.4K +85.2% |
$73.1K -55.9% |
$165.8K -46.5% |
$310.2K +272.5% |
$83.3K | — |
| Revenue (ASC 606) | $135.4K +85.2% |
$73.1K -55.9% |
$165.8K -46.5% |
$310.2K +272.5% |
$83.3K | — |
| Net Income | -$18.47M -495.0% |
-$3.10M -684.9% |
-$395.6K +97.7% |
-$17.31M -169.0% |
-$6.44M +40.5% |
-$10.81M -103.4% |
| Total Assets | $1.28M -36.2% |
$2.01M -23.0% |
$2.61M -20.4% |
$3.27M -22.8% |
$4.24M -8.0% |
$4.61M +1347.3% |
| Cash and Equivalents | — | $85.9K +540.4% |
$13.4K -29.0% |
$18.9K -95.0% |
$379.2K +320.5% |
$90.2K +62.4% |
| Stockholders Equity | -$32.18M -104.0% |
-$15.77M -9.7% |
-$14.37M +29.9% |
-$20.50M -80.0% |
-$11.39M -19.3% |
-$9.55M -11.5% |
| Operating Income | -$3.26M -46.6% |
-$2.23M +23.5% |
-$2.91M +23.5% |
-$3.81M +8.4% |
-$4.16M +9.7% |
-$4.60M +14.9% |
| Gross Profit | $125.4K +115.7% |
$58.1K -42.1% |
$100.4K -53.7% |
$216.8K +208.2% |
$70.3K | — |
| Shares Outstanding | 213.23M +186.2% |
74.50M +203.6% |
24.54M +1963.3% |
1.19M +175.9% |
431,063 -99.9% |
316.95M +193.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2023 | $1.5K | -86.1% | -96.6% |
| Revenue (ASC 606) | September 30, 2023 | $1.5K | -86.1% | -96.6% |
| Net Income | September 30, 2023 | -$766.2K | -27.0% | -137.1% |
| Diluted EPS | September 30, 2023 | $0.00 | — | +100.0% |
| Total Assets | September 30, 2023 | $815.8K | -43.8% | -19.6% |
| Cash and Equivalents | September 30, 2023 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2023 | -$22.96M | -17.1% | -2.4% |
| Operating Income | September 30, 2023 | -$472.8K | +4.8% | +58.2% |
| Gross Profit | September 30, 2023 | $693.00 | -90.0% | -98.5% |
| Shares Outstanding | September 30, 2023 | 318.75M | +100.2% | +14.3% |
- ENDONOVO THERAPEUTICS, INC. reported Total Revenue of $135.4 thousand for fiscal year 2022.
- ENDONOVO THERAPEUTICS, INC. showed an increase of +85.2% in Total Revenue compared to the prior fiscal year.
- ENDONOVO THERAPEUTICS, INC. reported Revenue (ASC 606) of $135.4 thousand for fiscal year 2022.
- ENDONOVO THERAPEUTICS, INC. showed an increase of +85.2% in Revenue (ASC 606) compared to the prior fiscal year.
- ENDONOVO THERAPEUTICS, INC. reported Net Income of -$18.47 million for fiscal year 2022.
- ENDONOVO THERAPEUTICS, INC. showed a decrease of -495.0% in Net Income compared to the prior fiscal year.
- ENDONOVO THERAPEUTICS, INC. reported Total Assets of $1.28 million for fiscal year 2022.
- ENDONOVO THERAPEUTICS, INC. showed a decrease of -36.2% in Total Assets compared to the prior fiscal year.
- ENDONOVO THERAPEUTICS, INC. reported Cash and Equivalents of $85.9 thousand for fiscal year 2021.
- ENDONOVO THERAPEUTICS, INC. showed an increase of +540.4% in Cash and Equivalents compared to the prior fiscal year.
- ENDONOVO THERAPEUTICS, INC. reported Stockholders Equity of -$32.18 million for fiscal year 2022.
- ENDONOVO THERAPEUTICS, INC. showed a decrease of -104.0% in Stockholders Equity compared to the prior fiscal year.
- ENDONOVO THERAPEUTICS, INC. reported Operating Income of -$3.26 million for fiscal year 2022.
- ENDONOVO THERAPEUTICS, INC. showed a decrease of -46.6% in Operating Income compared to the prior fiscal year.
- ENDONOVO THERAPEUTICS, INC. reported Gross Profit of $125.4 thousand for fiscal year 2022.
- ENDONOVO THERAPEUTICS, INC. showed an increase of +115.7% in Gross Profit compared to the prior fiscal year.
- ENDONOVO THERAPEUTICS, INC. reported Shares Outstanding of 213.23 million shares for fiscal year 2022.
- ENDONOVO THERAPEUTICS, INC. showed an increase of +186.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: